Researchers defined a link between high insulin levels and defective lipid metabolism but the cause may not be exactly what you think. According to a study published in June, 2005 -- this could be due to their choice in blood sugar lowering medication.

The conclusion of the study identified obese insulin-resistant subjects taking metformin (brand names Glucophage, Diabex, Diaformin, Fortamet, Riomet, Glumetza) and rosiglitazone both improve insulin sensitivity (increase insulin production) but DO NOT improve lipid metabolism. Rosiglitazone (brand name Avandia) may have a detrimental effect on chylomicron metabolism

Blood vessels of insulin-resistant rats build up a substance called chylomicron cholesterol following a high fat meal. Because the rats are insulin-resistant, more insulin (in the form of an anti-diabetes pill) is required to clear sugars and fats from their bloodstream. Higher insulin levels reduced the rate of chylomicron removal from the blood stream following a meal. This slower clearing rate increased the chylomicron particles sticking around the blood vessels, leading to arterial plaque build up and heart disease.

Knowing that high levels of insulin are associated with elevated levels of chylomicron cholesterol, researchers will use this information to try to figure out how this happens.

Why would they do that? The answer was already explained in June, 2005. Oh it must be because arterial plaque builds differently in Australian's on anti-diabetic pills than it does in American's on anti-diabetic pills. We should all thank the good folks at GlaxoSmithKline, Bristol-Myers Squibb, Pfizer and Merck. Without their medicine -- how would anybody ever know about this stuff? First you're on an anti-diabetic pill, then you're on cholesterol lowing pill, what's next? Of course -- the blood pressure!!

How many people are Gold Star type 2 diabetic patients?

Sink your teeth into this one. Generex, the company that is quickly making a name for itself as the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced that it has been granted the first patent for its medicinal gum platform. The patent is titled Compositions for Oral Transmucosal Delivery of Metformin. It covers claims to the composition, processes, and methodologies for the delivery of an oral transmucosal metformin composition via the oral mucosal membrane for absorption. Long story short: you chew it.

Metformin is a generic drug used to regulate blood sugar levels by reducing the amount of glucose produced by the liver. The popular brand names of Metformin include: Glucophage, Diabex, Diaformin, Fortamet, Riomet, and Glumetza. Metformin is the only anti-diabetic drug that has been proven to reduce the cardiovascular complications of diabetes, as evidenced in a large study of overweight patients with diabetes. Metformin has been in use around the world for more than 30 years. It remains the most prescribed drug for Type-2 diabetes, a testimony to its efficacy and its prominent place in diabetes therapy.

Rose C. Perri, the Generex Chief Operating Officer commented, "we are very pleased to receive the first patent for our metformin gum product, a product that compliments our flagship product, Generex Oral-lyn™, and related diabetes pipeline". On a personal note, when I first learned about this development from the masterminds at Generex I was definitely excited. But now that the train has left the station, I'm happy to share this news with the gum-chewing, metformin-taking, diabetes population. It's all about the delivery and this one is definitely special.

Researchers have found that extended-release metformin works just as well as conventional metformin in treating Type 2 diabetes. The regular dose of metformin is taken twice daily, whereas the extended-release type needs to be taken only once a day, up to 2000 mg per day. The extended-release metformin is sold under the brand name Glumetza. The results of a study on this topic were reported in Diabetes Care this month. Metformin works by controlling the amount of glucose in the blood. It does this by decreasing both the insulin absorbed from food and the amount of glucose manufactured in the liver. It can be prescribed for use on its own or in conjunction with insulin.